TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC50=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease[1].
References:
[1]. Tang K, et al. Discovery of Novel Pyrazole-Based KDM5B Inhibitor TK-129 and Its Protective Effects on Myocardial Remodeling and Fibrosis. J Med Chem. 2022 Sep 16.
TK-129 是一种口服有效的、低毒的强效 KDM5B 抑制剂 (具有高亲和力; IC50=44 nM)。TK-129 通过抑制 KDM5B 和阻断 KDM5B 相关的 Wnt 通路，来发挥心脏保护作用。TK-129 能在体外减少 Ang II 诱导的心脏成纤维细胞的活化，并在体内减少异丙肾上腺素诱导的心肌重塑和纤维化。TK-129 可用于心血管疾病的研究。